Blueprint Medicines (BPMC) Competitors $129.46 0.00 (0.00%) As of 07/18/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BPMC vs. ONC, BNTX, SMMT, INSM, TEVA, GMAB, MRNA, RDY, QGEN, and VTRSShould you be buying Blueprint Medicines stock or one of its competitors? The main competitors of Blueprint Medicines include BeOne Medicines (ONC), BioNTech (BNTX), Summit Therapeutics (SMMT), Insmed (INSM), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry. Blueprint Medicines vs. Its Competitors BeOne Medicines BioNTech Summit Therapeutics Insmed Teva Pharmaceutical Industries Genmab A/S Moderna Dr. Reddy's Laboratories Qiagen Viatris Blueprint Medicines (NASDAQ:BPMC) and BeOne Medicines (NASDAQ:ONC) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings. Is BPMC or ONC more profitable? BeOne Medicines has a net margin of -9.40% compared to Blueprint Medicines' net margin of -27.70%. BeOne Medicines' return on equity of -7.55% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Blueprint Medicines-27.70% -64.60% -17.22% BeOne Medicines -9.40%-7.55%-4.42% Do insiders and institutionals hold more shares of BPMC or ONC? 48.6% of BeOne Medicines shares are owned by institutional investors. 4.2% of Blueprint Medicines shares are owned by company insiders. Comparatively, 6.6% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has higher earnings and valuation, BPMC or ONC? Blueprint Medicines has higher earnings, but lower revenue than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than Blueprint Medicines, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlueprint Medicines$562.12M14.87-$67.09M-$2.47-52.41BeOne Medicines$3.81B8.60-$644.79M-$3.72-80.38 Does the media refer more to BPMC or ONC? In the previous week, BeOne Medicines had 11 more articles in the media than Blueprint Medicines. MarketBeat recorded 12 mentions for BeOne Medicines and 1 mentions for Blueprint Medicines. BeOne Medicines' average media sentiment score of 0.42 beat Blueprint Medicines' score of 0.00 indicating that BeOne Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Blueprint Medicines 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BeOne Medicines 6 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate BPMC or ONC? Blueprint Medicines presently has a consensus price target of $130.00, suggesting a potential upside of 0.42%. BeOne Medicines has a consensus price target of $327.56, suggesting a potential upside of 9.55%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts plainly believe BeOne Medicines is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blueprint Medicines 0 Sell rating(s) 16 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11BeOne Medicines 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, BPMC or ONC? Blueprint Medicines has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500. SummaryBeOne Medicines beats Blueprint Medicines on 11 of the 16 factors compared between the two stocks. Get Blueprint Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BPMC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPMC vs. The Competition Export to ExcelMetricBlueprint MedicinesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.36B$3.00B$5.49B$9.52BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-52.4117.6228.7823.81Price / Sales14.87179.21372.2066.04Price / CashN/A41.9535.4557.96Price / Book27.548.508.275.54Net Income-$67.09M-$55.06M$3.25B$259.28M7 Day PerformanceN/A-3.99%-3.70%-4.64%1 Month Performance0.98%9.58%4.34%4.41%1 Year Performance33.85%6.70%25.90%17.95% Blueprint Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPMCBlueprint Medicines0.7266 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640Upcoming EarningsONCBeOne Medicines0.7258 of 5 stars$294.51+1.0%$327.56+11.2%N/A$32.28B$3.81B-79.1711,000News CoverageUpcoming EarningsInsider TradeGap UpBNTXBioNTech2.7516 of 5 stars$112.79-2.2%$136.58+21.1%+33.0%$27.11B$2.98B-33.176,772Upcoming EarningsGap DownSMMTSummit Therapeutics2.8961 of 5 stars$27.45-4.3%$34.67+26.3%+153.9%$20.39B$700K-80.73110Positive NewsUpcoming EarningsINSMInsmed3.8031 of 5 stars$101.75-2.1%$109.20+7.3%+44.3%$19.30B$363.71M-17.101,271Positive NewsUpcoming EarningsTEVATeva Pharmaceutical Industries3.9815 of 5 stars$16.53-0.1%$24.71+49.5%-12.3%$18.96B$16.62B-14.3736,830News CoveragePositive NewsEarnings ReportGMABGenmab A/S3.6799 of 5 stars$23.09-1.3%$37.80+63.7%-23.2%$14.81B$3.12B13.122,682News CoveragePositive NewsShort Interest ↑MRNAModerna4.4709 of 5 stars$33.91-0.7%$46.11+36.0%-70.7%$13.11B$3.24B-3.885,800Trending NewsEarnings ReportAnalyst ForecastOptions VolumeGap DownRDYDr. Reddy's Laboratories1.9785 of 5 stars$14.71+0.2%$16.95+15.3%-15.5%$12.28B$3.81B22.2827,811QGENQiagen3.2221 of 5 stars$51.00-1.5%$49.40-3.1%+12.1%$11.51B$2.00B127.875,765News CoverageUpcoming EarningsVTRSViatris2.2182 of 5 stars$9.26-1.6%$10.40+12.3%-26.3%$10.87B$14.74B-2.9232,000Upcoming EarningsShort Interest ↑ Related Companies and Tools Related Companies ONC Competitors BNTX Competitors SMMT Competitors INSM Competitors TEVA Competitors GMAB Competitors MRNA Competitors RDY Competitors QGEN Competitors VTRS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BPMC) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Blueprint Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BPMC Stock Alerts